Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2016
Eisai Inc. announced today the presentation of seven abstracts featuring data on its cancer treatments at the European Society of Medical Oncology (ESMO) 2016 Congress. The abstracts highlight new...
-
Sep 29, 2016Eisai's CLEAR study will compare the company's multiple receptor TKI, lenvatinib, plus the anti-PD-1 pembrolizumab and lenvatinib plus the mTOR inhibitor everolimus versus sunitinib, the current standard of care in this setting
Eisai Inc. announced today the initiation of a multicenter, global, randomized Phase 3 study that will evaluate the efficacy and safety of two regimens containing Eisai's multiple receptor...
- Sep 26, 2016Application Based on New FDA Communication Supporting Use as Monotherapy for the Treatment of Partial Onset Seizures Based on Extrapolation
Eisai Inc. announced today that it has submitted a supplemental application to the U.S. Food and Drug Administration (FDA) for a proposed label change for its antiepileptic drug FYCOMPA®...
-
Sep 22, 2016METAvivor and Eisai Inc. Partner to Urge MBC Community to Discuss Living with Their Diagnosis, How They Draw Strength and Encouragement from Their Support Networks
"The cancer has spread. We can offer you treatment, but ultimately, it is incurable." A metastatic breast cancer (MBC) diagnosis comes with many medical, practical and emotional challenges as...
- Sep 21, 2016The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors' Association, and Eisai Team Up to Increase Awareness by Urging People with Thyroid Cancer to Share their Experiences
A thyroid cancer diagnosis can lead to significant distress as patients and caregivers cope with various medical, emotional and economic challenges, as survivors, patients and caregivers have...
-
Sep 21, 2016
Eisai Inc. announced today the presentation of abstracts at the 86th Annual Meeting of the American Thyroid Association (ATA) that highlight an investigational Phase 2 trial currently recruiting...
- Sep 15, 2016Discovery innovation unit of 90 scientists at dedicated research facility to use human genetics and related data to develop novel, targeted medicines for dementia and oncology
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the...
- Sep 14, 2016
Eisai Inc. today announced that new data presented at the 12th European Congress on Epileptology (ECE) showed that long-term adjunctive use of FYCOMPA® (perampanel) CIII for up to two and a half...
- Jul 28, 2016Child Neurology Foundation Initiative Provides Guidance for Pediatric Neurology Patients
The Child Neurology Foundation (CNF) announced today that a consensus statement addressing the role of the neurologist in transitioning children to the adult healthcare system has been published...
Jul 19, 2016Once-a-Day Tablet Offers Millions of Americans a New Option to Address Chronic Weight ManagementEisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for BELVIQ XR® (lorcaserin...
- Jul 14, 2016Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in MexicoFirst Country in Latin America to Approve lorcaserin
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the...
- Jun 29, 2016Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day-- "Ricchi" philosophy focuses on hardest-to-treat medical conditions, including dementia
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today held a Scientific Day to present its approach to global R&D and introduce the company's robust neurology and oncology...
- Jun 22, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it will host a Scientific Day on June 29, 2016 from 9:00 a.m. EDT to 12:45 p.m. EDT in New York City, and...
- Jun 15, 2016New FDA-Approved Formulation Indicated as Adjunctive Therapy for the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures
Eisai Inc. announced today the availability of FYCOMPA® (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty...
- Jun 14, 2016Two-day forum conducted to identify innovative resources that may help patients with rare, severe form of epilepsy
Eisai Inc. and the Lennox-Gastaut Syndrome (LGS) Foundation held a hackathon event, called #HackLGS, bringing together LGS caregivers, technology developers, students and creative specialists on...
-
Jun 2, 2016Combination treatment recently approved by FDA for Patients with Advanced Renal Cell Carcinoma Following Prior Anti-angiogenic Therapy
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Novartis Pharmaceuticals Corporation, an affiliate of Basel, Switzerland-based Novartis AG, have entered into an agreement to...
-
May 24, 2016- Abstracts include sub-analysis from second pivotal trial of Halaven® to show overall survival advantage, which supported January FDA approval in advanced liposarcoma
Eisai Inc. announced today presentations of new analyses of studies supporting U.S. Food and Drug Administration (FDA) approvals at the 2016 American Society of Clinical Oncology (ASCO) Annual...
- May 24, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Maria Garrigan, as Vice President, Global Regulatory Strategy for the Oncology...
-
May 13, 2016- Near-tripling in progression-free survival demonstrated by LENVIMA and everolimus when compared with a standard of care advances treatment paradigm in this category
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with...
- May 2, 2016New Formulation Expands Treatment Options for Epilepsy Patients with POS and PGTC Seizures
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII Oral Suspension as adjunctive therapy for the treatment of partial-onset...
- Apr 20, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the...
Apr 14, 2016Fourth Comic Book in the Series “Medikidz Explain Epilepsy” Launching at the 2016 National Walk for Epilepsy in Washington, D.C.-
Apr 11, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Beyhan Zaim as Vice President Commercial Development & Alzheimer's Disease Global...
- Apr 6, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Paul Hawthorne to the position of Senior Vice President, U.S. Commercial, Neurology...
-
Mar 18, 2016--Helsinn Therapeutics Inc. to obtain all rights to promote and distribute AKYNZEO® (netupitant/palonosetron) --
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, and Eisai Inc., the U.S. pharmaceutical subsidiary of the research-based human healthcare company Eisai Co., Ltd ,...
-
Feb 10, 2016Pivotal Data Led to Recent FDA Approval for This Indication
Eisai Inc. announced today that results from its pivotal Phase 3 study (Study 309) investigating the use of Halaven® (eribulin mesylate) Injection (0.5 mg per mL) in certain types of soft tissue...
-
Jan 29, 2016- Halaven is the first and only single agent to prolong overall survival in patients with previously treated advanced (unresectable or metastatic) liposarcoma in a Phase 3 trial
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Halaven® (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or...
-
Jan 17, 2016Supplemental application based on progression-free survival data from Study 205, a three-arm Phase 2 study comparing lenvatinib in combination with everolimus, everolimus alone and lenvatinib alone in these patients
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for lenvatinib for the potential treatment...
-
Dec 9, 2015
Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Eisai Inc. will present a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin...
- Dec 2, 2015
Eisai Inc. announced today that 21 posters highlighting perampanel data and an interim analysis from the first and largest caregiver burden study in epilepsy will be presented at the 69th Annual...
-
Dec 1, 2015Long-Term, Large-Scale Outcomes Study Assesses Cardiovascular and Metabolic Effects of BELVIQ in Overweight and Obese Patients
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the CAMELLIA-TIMI 61 study has reached its target enrollment of 12,000 patients at more than 470 sites in eight...
-
Nov 30, 2015
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for an extended...
- Nov 18, 2015Clinical Study (MORAb-009-201) of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma (MPM)
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind ARTEMIS—Amatuximab Research in Treatment-naïve Epithelial...
- Nov 17, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg in Sweden to...
-
Nov 13, 2015
Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical practice guidelines for antiemetics in oncology...
- Nov 9, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company...
-
Nov 4, 2015The parties hope to develop new cancer targets and novel therapeutic approaches
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has initiated a research collaboration for research and development with the Paoli Calmettes Institute (IPC),...
- Oct 26, 2015
Eisai Inc. announced today that Halaven® (eribulin mesylate) Injection has been nominated by the Galien Foundation within the category, "Best Pharmaceutical Agent of the Year" at the ninth annual...
- Oct 26, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor antigen on the investigational...
-
Oct 19, 2015Findings suggest need for improved dialogue between patients receiving chemotherapy and their healthcare team, including pharmacists
-
Oct 16, 2015
Results from an investigational Phase 2 clinical trial evaluating lenvatinib in combination with everolimus and lenvatinib and everolimus alone for the treatment of metastatic renal cell carcinoma...
-
Oct 15, 2015
Eisai Inc. announced today the presentation of a company-record seven abstracts at the 15th International Thyroid Congress (ITC), highlighting the importance of the Phase 3 SELECT trial of...
-
Oct 8, 2015
Eisai Inc. announced the decision of the National Comprehensive Cancer Network® (NCCN®) to recommend LENVIMA™ (lenvatinib) as the preferred agent for the treatment of patients with progressive...
- Sep 28, 2015
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for eribulin mesylate (eribulin) being evaluated...
- Sep 24, 2015Eisai, CancerCare®, Cancer Support Community®, Cornucopia Cancer Support Center™ and Meals on Wheels America Continue their Commitment to Providing Meal Assistance to Enable Loved Ones to Spend More Quality Time Together
Magnolia Meals at Home®, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now helping those living with thyroid cancer. Sponsored...
- Sep 14, 2015
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for FYCOMPA® (perampanel) CIII Oral Suspension 0.5...
-
Aug 31, 2015Companies to develop lemborexant for the potential treatment of insomnia and explore other future indications
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered into a worldwide collaboration agreement for the development and...
- Aug 24, 2015Global Multicenter Study of FYCOMPA as Adjunctive Therapy Published in Neurology
Eisai Inc. announced today that the results of its Phase 3 trial (Study 332) for FYCOMPA® (perampanel) CIII have been published in the online edition of Neurology, the medical journal of the...
-
Jul 31, 2015Clinical trial will explore whether or not eribulin in combination with PEGPH20 can improve overall response rate in women with advanced breast cancer
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San Diego,...
-
Jul 30, 2015
Eisai Inc. announced today that regulatory applications were submitted simultaneously in the United States, European Union and Japan (to the FDA, EMA and MHLW, respectively) for eribulin, for the...
